Blood tests could replace frequent scans for some breast cancer patients
NCT ID NCT04597580
Summary
This study aims to develop a blood test system to monitor advanced breast cancer, potentially reducing the need for frequent CT/MRI scans. It involves 97 patients with ER-positive/HER2-negative metastatic breast cancer who are starting first-line hormone therapy. Researchers will track three blood markers (ctDNA, TK1, CA15-3) at every scheduled scan time to create an algorithm that predicts when scans are truly necessary versus when they can be safely skipped.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Oncology, Kalmar Hospital
Kalmar, Sweden
-
Department of Oncology, Linköping University Hospital
Linköping, Sweden
-
Department of Oncology, Ryhov Hospital
Jönköping, Sweden
-
Department of Oncology, Sahlgrenska University Hospital
Gothenburg, Sweden
-
Department of Oncology, Södersjukhuset
Stockholm, Sweden
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
Wigan Infirmary, Wrightington, Wigan and Leigh NHS Foundation Trust
Wigan, United Kingdom
Conditions
Explore the condition pages connected to this study.